H-STHVNHLHC-OH

Ref. 3D-PP46968

Produktinformation

• Name: H-STHVNHLHC-OH
• Synonyme: NH2-Ser-Thr-His-Val-Asn-His-Leu-His-Cys-OH

Beschreibung

Peptide H-STHVNHLHC-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-STHVNHLHC-OH include the following: Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines SD Martin , SD Brown , DA Wick , JS Nielsen - PloS one, 2016 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155189 SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade M Fassaca², R Waitz, Y Hou, T Rim - Proceedings of the , 2008 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0712269105 AR inhibition increases MHC class I expression and improves immune response in prostate cancer LN Chesner, JN Graff, F Polesso, A Smith, A Lundberg - 2023 - papers.ssrn.comhttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=4403436 Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted Immunotherapy DA Emerson, AS Rolig , WL Redmond - Cancer Immunology Research, 2021 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/9/4/430/666173 Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer BW Simons , F Cannella, DT Rowley - Cancer Immunology , 2020 - Springerhttps://link.springer.com/article/10.1007/s00262-020-02493-z Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells BJ Burbach , SD O'Flanagan , Q Shao , KM Young - Nature , 2021 - nature.comhttps://www.nature.com/articles/s41467-021-24132-6

• Marke: Biosynth